Stockscreener 앱 받기
1.48
4.96%
0.07
전일 마감가:
$1.41
열려 있는:
$1.41
하루 거래량:
536.77K
Relative Volume:
0.58
시가총액:
$68.05M
수익:
$84.32M
순이익/손실:
$-3.16M
주가수익비율:
-29.60
EPS:
-0.05
순현금흐름:
$-4.50M
1주 성능:
-1.33%
1개월 성능:
-7.50%
6개월 성능:
+23.08%
1년 성능:
-1.33%
1일 변동 폭
$1.38
$1.54
1주일 범위
$1.31
$1.54
52주 변동 폭
$1.08
$2.18
Theratechnologies Inc Stock (THTX) Company Profile
THTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
THTX
Theratechnologies Inc
|
1.48 | 68.05M | 84.32M | -3.16M | -4.50M | -0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Theratechnologies Inc Stock (THTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-11-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-07-29 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
Theratechnologies Inc 주식(THTX)의 최신 뉴스
Theratechnologies Inc expected to post earnings of 3 cents a shareEarnings Preview - TradingView
Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update - couriernews.com
Theratechnologies Q1 Earnings: CEO and Executive Team to Reveal Latest Financial Performance - Stock Titan
Short Interest in Theratechnologies Inc. (NASDAQ:THTX) Drops By 13.6% - Defense World
AIGH Capital Management LLC Trims Holdings in Theratechnologies Inc. (NASDAQ:THTX) - MarketBeat
Virtu Financial LLC Invests $40,000 in Theratechnologies Inc. (NASDAQ:THTX) - Defense World
Theratechnologies Gains FDA Approval for New Tesamorelin Formulation - TipRanks
Theratechnologies rises after FDA label expansion for best seller Egrifta - MSN
Theratechnologies stock rises on FDA label expansion (THTX) - Seeking Alpha
Theratechnologies Receives FDA Approval for EGRIFTA WR - Contract Pharma
Sector Update: Health Care Stocks Advance Pre-Bell Wednesday - MarketScreener
New Egrifta formulation picks up US FDA nod - The Pharma Letter
TSX futures flat as markets await clarity on tariffs - MarketScreener
US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert - Benzinga
Theratechnologies gets FDA nod for new treatment of abdominal fat in HIV patients, shares soar - TradingView
FDA Approves F8 Formulation of Theratechnologies' Tesamorelin for HIV-Associated Lipodystrophy - ContagionLive
FDA approves new tesamorelin formulation by Theratechnologies - Investing.com Australia
Theratechnologies Gains FDA Nod for Enhanced HIV Treatment - TipRanks
FDA approves new tesamorelin formulation by Theratechnologies By Investing.com - Investing.com South Africa
Theratechnologies Receives FDA Approval for EGRIFTA WR™ - GlobeNewswire
Theratechnologies Shares Rise on FDA Approval for HIV-Induced Stomach Fat Treatment - MarketWatch
Theratechnologies announces FDA approval of sBLA for F8 formulation of tesamorel - TipRanks
Theratechnologies Receives FDA Approval For EGRIFTA WR (Tesamorelin F8) To Treat Excess Visceral Abdominal Fat In Adults With HIV And Lipodystrophy - Marketscreener.com
Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess - Bluefield Daily Telegraph
Major FDA Win: New Weekly HIV Drug Cuts Treatment Burden by 85% - Stock Titan
Theratechnologies Inc. - Baystreet.ca
Stocks In Play: Theratechnologies Inc. - Barchart
Theratechnologies CROI Presentation Highlights Limitations - GlobeNewswire
Theratechnologies Reports Encouraging Results From PROMISE-US Trial Of Ibalizumab - Nasdaq
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV - The Manila Times
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of - The Bakersfield Californian
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI - GlobeNewswire
Theratechnologies Presents Encouraging Virologic - GlobeNewswire
Theratechnologies Inc. to Host Earnings Call - ACCESS Newswire
Theratechnologies, Inc. to Host Earnings Call - ACCESS Newswire
Research Analysts Issue Forecasts for THTX FY2027 Earnings - Defense World
FY2025 EPS Estimates for TSE:TH Reduced by Leede Financial - MarketBeat
Theratechnologies (NASDAQ:THTX) Posts Quarterly Earnings Results, Misses Expectations By $0.14 EPS - MarketBeat
Leede Financial Brokers Reduce Earnings Estimates for TSE:TH - Defense World
Theratechnologies (NASDAQ:THTX) Issues Earnings Results - MarketBeat
Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update - MarketBeat
Theratechnologies Inc. (NASDAQ:THTX) Short Interest Up 212.7% in February - Defense World
Research Analysts Set Expectations for THTX FY2025 Earnings - Defense World
Theratechnologies’ Earnings Call: Growth Amid Challenges - TipRanks
What is Leede Financial's Estimate for THTX FY2025 Earnings? - MarketBeat
Theratechnologies Inc (THTX) Q4 2024 Earnings Call Highlights: Strong EBITDA Turnaround and ... - Yahoo Finance
Theratechnologies Reports Strong Fiscal 2024 Performance - TipRanks
Theratechnologies reports Q4 revenue $25M vs $23.45M last year - TipRanks
Theratechnologies: Fiscal Q4 Earnings Snapshot - mySA
Theratechnologies Inc reports results for the quarter ended November 30Earnings Summary - TradingView
Earnings call transcript: Theratechnologies Q4 2024 sees growth amid strategic shifts - Investing.com UK
Theratechnologies Inc (THTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):